We found that patients with KLK6-positive tumours more frequently had late stage (stage III/IV) disease (P<0.001) (Figure 2B), higher tumour grades (P=0.04), suboptimal debulking (P=0.002), and serous and undifferentiated histotypes (P<0.001) (Figure 2C); but KLK6 expression had no relationship with response to chemotherapy. The gene discussed is KLK6; the disease is neoplasm.